Experimental Antitumor Activity against Murine Tumor Model Systems of 8-Carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (Mitozolomide), a Novel Broad-Spectrum Agent

Cancer Research

Volumn 45, Issue 7, 1985, Pages 3008-3013

  Hickman, John A ^a   Stevens, Malcolm F G ^a   Gibson, Neil W ^a   Langdon, Simon P ^a   Fizames, Christian ^b   Lavelle, Francois ^b   Atassi, Ghanem ^c   Lunt, Edward ^d   Tilson, Robert M ^d  

^a ASTON UNIVERSITY   (United Kingdom)

^b Centre de Recherches de Wry ^*  (France)

^c JULES BORDET INSTITUTE   (Belgium)

^d May and Baker Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACARBAZINE DERIVATIVE; DOXORUBICIN; METHOTREXATE; MITOZOLOMIDE; MITOZOLOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BLOOD AND HEMOPOIETIC SYSTEM; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG RESISTANCE; LEUKEMIA; LEWIS CARCINOMA; LYMPHOMA; MELANOMA; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; SARCOMA; THERAPY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARMUSTINE; DRUG RESISTANCE; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; NITROGEN MUSTARD COMPOUNDS;

EID: 0021795414     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Stevens, M. F. G. The medicinal chemistry of 1, 2, 3-triazines. Prog. Med. Chem., 73; 205-269, 1976.
2. Vaughan, K., and Stevens, M. F. G. Monoalkyttriazenes. Chem. Soc. Rev., 7: 377-397, 1978.
3. Baig, G. U., Stevens, M. F. G., Stone, R., and Lunt, E. Triazines and related products. Part 24. Synthesis of pyraozol-ylidenehydrazidaoles by hy-drazinolysis of imidazo (5, 1-c][1, 2t4]triazines and 2-arylazoimidazoles by dia-zonium coupling reactions. J. Chem. Soc. Perkin Trans. 1, 1811-1819, 1982.
4. Farina, P., Gescher, A., Hickman, J. A., Horton, J. K., D'lncalci, M., Ross, D., Stevens, M. F. G., and Torti, L. Studies of the mode of action of antitumour triazenes and triazines-IV. The metabolism of 1-(4-acetyiphenyl)-3, 3-di-methyltriazene. Biochem. Pharmacol., 37; 1887-1892, 1982.
5. Gibson, N. W., and Hickman, J. A. The role of isocyanates in the toxicity of antitumour haloalkytnitrosoureas. Biochem. Pharmacol., 31; 2795-2800, 1982.
6. Stevens, M. F. G., Hickman, J. A., Stone, R., Gibson, N. W., Lunt, E., Newton, C. G., and Baig, G. U. Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamolyl-3-(2-chloroethyl)imidazo[5, 1-d-]-1, 2, 3, 5-tetrazin-4(3H)-one, a
7. Lowe, P., Schwalbe, C. H., and Stevens, M. F. G. Antitumor imidazotetrazines. Part 5. Crystal and molecular structure of 8-carbamolyl-3-2-(chloroethyl)-imi dazo[5, 1-d1, 2, 3, 5-tetrazin-4(3H)-one. J. Chem. Soc. Perkin II, 357-361, 1985.
8. Gibson, N. W., Erickson, L. C., and Hickman, J. A. Effects of the antitumour agent 8-carbamoyl-2chloroemyl)-imdazo[5, 1 -d]-1, 2, 3, 5-tetrazin-4-(3H)-one on the DNA of mouse L1210 cells. Cancer Res., 44: 1767-1771, 1984.
9. Gibson, N. W., Hickman, J. A., and Erickson, L. C. DNA cross-Inking and cytotoxocity in normal and transformed human eels treated in vitro with 8-carbamoyl-3-(2-chloroemyl)imidazo [5, 1-d]-1, 2, 3, 5-terazin-4(3H)-one. Cancer Res., 44: 1772-1775, 1984.
10. Horgan, C. M. T., and Tisdale, M. J. Antitumour Imidazotetrazines. 4. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent CCRG 81010 (M & B 39565; NSC 353451). Biochem. Pharmacol., 33: 2185-2192, 1984.
11. Shealy, Y. F., and Krauth, C. A. Completeinhibition of mouse leukaemia L1210 by 5 (or 4)[3, 34)is(2-chloroemyrh1-triaieno]-imidazole-4 (or 5) carboxamide (NSC 82196). Nature (Lond.), 270; 208-209, 1966.
12. Vogel, C. L., Denham, C., Waalkes, T. P., and DeVita, V. T. The physiological disposition of the carcinostatic imidazote-4 (or 5)-carboxamide, 5 (or 4)[(3, 3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs. Cancer Res., 30: 1651-1657, 1970.
13. Shealy, Y. F., O'Del, C. A., and Krauth, C. A. 5-(3-(2-Chloroethyl)-1-triazenyl] imidazole-4-carboxamide and a possible mechanism of action of 5-(3, 3-bis(2-(chloroemyl)-1-triazenyl]imidazole-4-carboxamide. J. Pharm. Sci., 64: 177-180, 1975.
14. Goddard, C., Slack, J. A., Newtands, E. S., Blackledge, G., Brindtey, C. J., and Stevens, M. F. G. Phase 1 Clinical pharmacokinetics of CCRG 81010 (M & B 39565, NSC 353451). Br. J. Cancer, 50: 243, 1984.
15. Slack, J. A., Stevens, M. F. G., Goddard, C., and Khan, A. The analysis and pharmacokinetics of CCRG 81010 (M & B 39565, NSC 353451)-a new antitumour compound. Proc. Am. Assoc. Cancer Res., 24: 291, 1983.
16. Geran, R. I., Greenberg, N. H., Macdonald, M. M., Schumacher, A. M., and Abbot, B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 3; 1-104, 1972.
17. Gescher, A., Gibson, N. W., Hickman, J. A., Langdon, S. P., Ross, D., and Atassi, G. N-Memylformamide: antitumor activity and metabolism in mice. Br. J. Cancer, 45: 843-850, 1982.
18. Langdon, S. P., Gescher, A., Hickman, J. A., and Stevens, M. F. G. The chemosensitivity of a new experimental model-the M5076 reticulum eel sarcoma. Eur. J. Cancer, 20: 699-705, 1984.
19. Wexler, H. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst, 36: 641-645, 1966.
20. Audette, R. C. S., Connors, T. A., Mandel, H. G., Merai, K., and Ross, W. C. J. Studies on the mechanism of action of the tumour inhibitory triazenes. Biochem. Pharmacol., 22: 1855-1864, 1973.
21. Litchfield, J. T., and Willcoxon, F. A simplified method of evaluating dose effect experiments. J. Pharmacol. Exp. Ther., 96: 99-113, 1949.
22. Weinkam, R. J., and Lin, H. S. Reactions of 1, 3-bis(2-chloroethyl)-l-nitrosourea and 1-(2-chloroethyi)-3-cyclohexyl-nitrosourea in aqueous solution. J. Med. Chem., 22: 1193-1198, 1979.
23. Kohn, K. W. Drug-Induced macromolecular damage of nuclear DNA. In: H. Busch, S. T. Crooke, and Y. Daskal (eds.), Effects of Drugs on the Cell Nucleus, pp. 224-239. New York: Academic Press, Inc., 1979.
24. Schabel, F. M., Jr. Nitrosoureas: a review of experimental antitumour activity. Cancer Treat. Rep., 60: 665-698, 1976.
25. Wheeler, G. P., Alexander, J. A., and Adamson, C. J. Effects of N, N'-bis-(chloroethyl)-N-nitrosourea and 2-[3-(2-chlorcethyl)-3Hiitrosoureido]-2 deoxy D-glucopyranose upon the proliferation, DNA synthesis and viability of cultured sensitive and resistant L1210 cells. Cancer Res., 40: 3723-3727, 1980.
26. Kohn, K. W. Mechanistic approaches to nitrosourea development. Recent Results Cancer Res., 76: 141-152, 1981.
27. Levin, V. A., Steams, J., Byrd, A., Finn, A., and Weinkam, R. J. The effect of phenobarbetal pretreatment on the antitumour activity of BCNU, CCNU and PCNU and on the pharmacokinetics and biotransformation of BCNU. J. Pharmacol. Exp. Ther., 208: 1-6, 1979.
28. GokJin, A., Venditti, J. M., MacDonald, J. S., Muggia, F. M., Herwey, J. E., and DeVita, V. T., Jr. Current results of the screening program of the Division of Cancer Treatment, National Cancer Institute. Eur. J. Cancer, 77; 129-142, 1981.